These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 30675296)
21. Values of ultrasound features and MMP-9 of papillary thyroid carcinoma in predicting cervical lymph node metastases. Zhang Y; Luo YK; Zhang MB; Li J; Li CT; Tang J; Li JL Sci Rep; 2017 Jul; 7(1):6670. PubMed ID: 28751724 [TBL] [Abstract][Full Text] [Related]
22. Predictive factors for central lymph node and lateral cervical lymph node metastases in papillary thyroid carcinoma. Feng JW; Yang XH; Wu BQ; Sun DL; Jiang Y; Qu Z Clin Transl Oncol; 2019 Nov; 21(11):1482-1491. PubMed ID: 30879178 [TBL] [Abstract][Full Text] [Related]
23. Diagnostic and prognostic value of Stanniocalcin 1 expression in papillary thyroid cancer. Sengun S; Korkmaz H; Ciris M; Yüceer RO; Boyluboy SM; Kiran M Endocrine; 2022 Oct; 78(1):95-103. PubMed ID: 35788886 [TBL] [Abstract][Full Text] [Related]
24. REGγ Is Associated with Lymph Node Metastasis and T-Stage in Papillary Thyroid Carcinoma. Qi L; He W Med Sci Monit; 2018 Mar; 24():1373-1378. PubMed ID: 29509725 [TBL] [Abstract][Full Text] [Related]
25. Association of CD1a-positive dendritic cells with papillary thyroid carcinoma in thyroid fine-needle aspirations: a cytologic and immunocytochemical evaluation. Pusztaszeri MP; Sadow PM; Faquin WC Cancer Cytopathol; 2013 Apr; 121(4):206-13. PubMed ID: 23042745 [TBL] [Abstract][Full Text] [Related]
26. [Risk factors for central neck lymph node metastases of papillary thyroid carcinoma]. Sun YS; Lyu HJ; Zhao YR; Zhang SS; Bai YX; Shi BY Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jun; 52(6):421-425. PubMed ID: 28635213 [No Abstract] [Full Text] [Related]
27. Skip lateral lymph node metastasis leaping over the central neck compartment in papillary thyroid carcinoma. Lei J; Zhong J; Jiang K; Li Z; Gong R; Zhu J Oncotarget; 2017 Apr; 8(16):27022-27033. PubMed ID: 28223546 [TBL] [Abstract][Full Text] [Related]
28. Investigation of the prognosis of patients with papillary thyroid carcinoma by tumor size. Ito Y; Fukushima M; Kihara M; Takamura Y; Kobayashi K; Miya A; Miyauchi A Endocr J; 2012; 59(6):457-64. PubMed ID: 22447137 [TBL] [Abstract][Full Text] [Related]
29. Downregulation of miR-381 is associated with poor prognosis in papillary thyroid carcinoma. Huang T; Yi D; Xu L; Bu E; Zhu C; Sang J; Zhang Y Int J Clin Exp Pathol; 2017; 10(12):11610-11616. PubMed ID: 31966518 [TBL] [Abstract][Full Text] [Related]
30. FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma. Ahmed M; Uddin S; Hussain AR; Alyan A; Jehan Z; Al-Dayel F; Al-Nuaim A; Al-Sobhi S; Amin T; Bavi P; Al-Kuraya KS J Clin Endocrinol Metab; 2012 Jan; 97(1):E1-E13. PubMed ID: 22049175 [TBL] [Abstract][Full Text] [Related]
31. Impact of Lin28 on lymph node metastasis in papillary thyroid carcinoma. Jin S; Xu C; Wang L; Wei J; Wang S Oncol Lett; 2021 Feb; 21(2):97. PubMed ID: 33376530 [TBL] [Abstract][Full Text] [Related]
32. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Maeta H; Ohgi S; Terada T Virchows Arch; 2001 Feb; 438(2):121-8. PubMed ID: 11253113 [TBL] [Abstract][Full Text] [Related]
33. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer. Lin SY; Wang YY; Sheu WH Clin Endocrinol (Oxf); 2003 Apr; 58(4):513-8. PubMed ID: 12641636 [TBL] [Abstract][Full Text] [Related]
34. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma. Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220 [TBL] [Abstract][Full Text] [Related]
35. [Clinicopathological factors in risk prediction of lymph node metastasis in papillary thyroid carcinoma]. Yue C; Zhang Y; Xing L; Zhao Y; Chen J; Jin Y; Liu H Zhonghua Yi Xue Za Zhi; 2014 Dec; 94(46):3637-41. PubMed ID: 25622954 [TBL] [Abstract][Full Text] [Related]
36. [Analysis of the patterns of cervical lymph node recurrence in patients with cN0 papillary thyroid carcinoma after central neck lymph node dissection]. Huang H; Xu Z; Wang X; Wu Y; Liu S Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):771-5. PubMed ID: 26813598 [TBL] [Abstract][Full Text] [Related]
37. Disparity expression of gammaH2AX in papillary thyroid cancer and nodular goiter. Hu S; Zhang G; Xu J; Zhu X; Lu X; Jiang L; Wang Q; Hou X; Cao J; Ge M Clin Lab; 2014; 60(12):2031-7. PubMed ID: 25651738 [TBL] [Abstract][Full Text] [Related]
38. Roles of phosphatidylinositol 3-kinase regulatory subunit alpha, activator protein-1, and programmed cell death 4 in diagnosis of papillary thyroid carcinoma. Chen X; Wu W; Chen X; Gong X Tumour Biol; 2016 May; 37(5):6519-26. PubMed ID: 26637226 [TBL] [Abstract][Full Text] [Related]
39. The accuracy of ultrasonography in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma: A meta-analysis. Wu LM; Gu HY; Qu XH; Zheng J; Zhang W; Yin Y; Xu JR Eur J Radiol; 2012 Aug; 81(8):1798-805. PubMed ID: 21536396 [TBL] [Abstract][Full Text] [Related]
40. Assessment of risk factors in metastatic/recurrent tall cell variant of papillary thyroid carcinoma. Okuyucu K; Alagoz E; Ince S; Arslan N Endokrynol Pol; 2017; 68(6):623-630. PubMed ID: 29022644 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]